Milan J. Anadkat MDDirector, Residency Program; Associate Professor, Division of Dermatology, Washington University School of Medicine, St. Louis, Missouri
Dr. Milan Anadkat serves as an Associate Professor of Dermatology at Washington University School of Medicine. He also serves as the Residency Program Director for Dermatology at Washington University School of Medicine. He graduated from the University of Akron and earned her medical degree at the Northeastern Ohio Universities College of Medicine. Dr. Anadkat performed his residency training at Washington University School of Medicine. He also completed a two-year clinical trials fellowship at Washington University School of Medicine.
In 2007, Dr. Anadkat joined the faculty of Washington University School of Medicine in St. Louis, MO as a Clinical Instructor of Dermatology. His clinical focus is in the area of medical dermatology: dermatologic therapeutics; psoriasis; collagen vascular disease; cutaneous lymphoma; autoimmune bullous disease; immunosuppression in the setting of organ-transplantation; graft-versus-host disease; and chemotherapy-induced adverse reactions.
Dr. Anadkat is a member of the American Academy of Dermatology, Medical Dermatology Society, American Board of Dermatology, and MASCC (Multinational Association of Supportive Care in Cancer). He has served on Work Groups and Task Forces for the American Academy of Dermatology, National Cancer Institute, and NCCN.
Dr. Anadkat’s publications include numerous research papers, book chapters, scientific abstracts and clinical reviews. He also lectures frequently nationally on a variety of related topics.
Recent Contributions to PracticeUpdate:
- Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With EGFR Inhibitors at a Cancer Center
- Dermatology Consultation Reduces Interruption of Oncologic Management Among Hospitalized Patients With Immune-Related Adverse Events
- Targeted Anticancer Agents May Cause Skin and Hair Pigmentary Changes
- Hair Repigmentation During Anti–PD-1 and Anti–PD-L1 Immunotherapy for Lung Cancer
- Methotrexate-Induced Epidermal Necrosis: A Case Series of 24 Patients
- Efficacy and Safety of Guselkumab vs Adalimumab for Continuous Treatment of Moderate to Severe Psoriasis
- Recognize the Range of Skin Reactions to EGFR Inhibitors
- Methotrexate in the Treatment of Pemphigus Vulgaris: Experience in 23 Patients